TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026 : average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension
tirzepatide trials are ongoing
If your genetic profile shows lower GLP1R sensitivity, viral infection may cause a more pronounced appetite rebound, and your PlexusDx medical team may recommend a slightly higher starting dose during recovery
DOI:10.4103/1673-5374.320969.
You get a plan that matches your health and goals
Journal of Clinical Psychopharmacology, 21 (3), 335-339